$ARDX

ARDELYX, INC.

Ardelyx is a commercial-stage biopharmaceutical company that develops and commercializes medicines for patients with unmet medical needs. Its two marketed U.S. therapies contain tenapanor, an NHE3 inhibitor discovered and developed by Ardelyx. IBSRELA is approved for adults with irritable bowel syndrome with constipation, while XPHOZAH is approved to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy for certain patients who do not respond adequately to phosphate binders or cannot tolerate them. Ardelyx earns money from product sales and from collaboration agreements, which provide for upfront payments, potential development and regulatory milestones, royalties and commercialization milestones; it also supplies drug substance or finished products to partners for a fee. Partners commercialize tenapanor in certain territories outside the U.S. Ardelyx is developing a next-generation NHE3 inhibitor and evaluating tenapanor for chronic idiopathic constipation. Its headquarters are in Fremont, California.

1
1
0

No SEC Form 4 filings for $ARDX in the last 30 days.

See all $ARDX insider activity →
Low

Ardelyx Targets 2027 Profitability as IBSRELA Faces Insurance Hurdles

Ardelyx (ARDX) aims for profitability by 2027, with IBSRELA facing insurance challenges. The company reported a 32% gross-to-net rate, allowing some pricing flexibility. Ardelyx completed enrollment in a Phase 3 trial for IBSRELA in chronic idiopathic constipation, with data expected in 2027. The company expects IBSRELA to reach $1 billion in sales but removed a specific timeframe. Ardelyx had $285 million in cash at the end of September and plans to use future cash flow for pipeline expansion.

Jefferies reiterates Ardelyx stock rating on contracting strategy

Jefferies maintained a Buy rating and $8.00 price target for Ardelyx (ARDX), citing its contracting strategy. The firm expects conservative 2027 guidance and Phase III CIC topline data. Ardelyx reported a 19% revenue increase to $125.5M in Q3, missing estimates but narrowing net loss to $700K. The stock is down 50% YTD.

Ardelyx Earnings Call Highlights IBSRELA Growth and Profit Path

Ardelyx Inc (ARDX) reported Q3 revenue growth of 19%, with IBSRELA revenue up 23% YoY to $96.3M. XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed 2026 guidance and profitability target for 2027, while noting payer friction and reimbursement challenges.

ARDX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARDX (ARDELYX, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent ARDX coverage spans financial news, earnings and technology.

What's driving ARDX

AlphAI scores every news story that mentions ARDX with an AI model for sentiment and relevance, and aggregates insider trades from ARDELYX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ARDX

Score

Ardelyx Targets 2027 Profitability as IBSRELA Faces Insurance Hurdles

Ardelyx (ARDX) aims for profitability by 2027, with IBSRELA facing insurance challenges. The company reported a 32% gross-to-net rate, allowing some pricing flexibility. Ardelyx completed enrollment in a Phase 3 trial for IBSRELA in chronic idiopathic constipation, with data expected in 2027. The company expects IBSRELA to reach $1 billion in sales but removed a specific timeframe. Ardelyx had $285 million in cash at the end of September and plans to use future cash flow for pipeline expansion.

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.

Ardelyx: Q3 Earnings Snapshot

Ardelyx Inc. (ARDX) reported a Q3 loss of $737,000, or less than 1 cent per share, beating analyst estimates of a 3 cent loss. Revenue was $127.7M, exceeding expectations of $124.5M. Shares closed at $3.03, down from $5.92 a year ago, according to Zacks Investment Research.

$ARDXMedEarnings

Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million Strong financial position wit

Ardelyx completes enrollment in constipation drug trial

Ardelyx Inc. (ARDX) completed enrollment in its Phase 3 ACCEL trial for IBSRELA (tenapanor) in treating chronic idiopathic constipation, ahead of schedule. Topline data is expected in the second half of 2027. IBSRELA is currently approved for irritable bowel syndrome with constipation in adults. The trial's primary endpoint is assessing the drug's durable efficacy in relieving constipation.

Ardelyx to present hyperphosphatemia research at ASN meeting

Ardelyx Inc. (ARDX) will present research on hyperphosphatemia treatment at the American Society of Nephrology Kidney Week 2026. Presentations include studies on tenapanor's effectiveness, patient perspectives, and long-term impacts. The company will also host an exhibitor session on XPHOZAH (tenapanor). XPHOZAH is FDA-approved for reducing serum phosphorus in dialysis patients, with diarrhea as the most common side effect.

Related tickers